期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 70, 期 14, 页码 1732-1740出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.08.009
关键词
cholesterol; Dutch Lipid Clinic; genetics; low-density lipoprotein cholesterol; Simon Broome criteria
资金
- Instituto de Salud Carlos III [RD012/0042/0066, CB16/11/00432]
- Spanish Ministry of Economy and Competitiveness [SAF2015-71863-REDT]
- Alexion through an Investigator Initiated Research Grant
- Instituto de Salud Carlos III - Plan Estatal de I+D+I European Regional Development Fund (FEDER), A way of making Europe
- Spanish Ministry of Economy and Competitiveness - Plan Estatal de I+D+I European Regional Development Fund (FEDER), A way of making Europe
BACKGROUND Genetic screening programs in unselected individuals with increased levels of low-density lipoprotein cholesterol (LDL-C) have shown modest results in identifying individuals with familial hypercholesterolemia (FH). OBJECTIVES This study assessed the prevalence of genetically confirmed FH in patients with acute coronary syndrome (ACS) and compared the diagnostic performance of FH clinical criteria versus FH genetic testing. METHODS Genetic study of 7 genes (LDLR, APOB, PCSK9, APOE, STAP1, LDLRAP1, and LIPA) associated with FH and 12 common alleles associated with polygenic hypercholesterolemia was performed in 103 patients with ACS, age <= 65 years, and LDL-C levels >= 160 mg/dl. Dutch Lipid Clinic (DLC) and Simon Broome (SB) FH clinical criteria were also applied. RESULTS The prevalence of genetically confirmed FH was 8.7% (95% confidence interval [CI]: 4.3% to 16.4%; n = 9); 29% (95% CI: 18.5% to 42.1%; n = 18) of patients without FH variants had a score highly suggestive of polygenic hypercholesterolemia. The prevalence of probable to definite FH according to DLC criteria was 27.2% (95% CI: 19.1% to 37.0%; n = 28), whereas SB criteria identified 27.2% of patients (95% CI: 19.1% to 37.0%; n = 28) with possible to definite FH. DLC and SB algorithms failed to diagnose 4 (44%) and 3 (33%) patients with genetically confirmed FH, respectively. Cascade genetic testing in first-degree relatives identified 6 additional individuals with FH. CONCLUSIONS The prevalence of genetically confirmed FH in patients with ACS age <= 65 years and with LDL-C levels >= 160 mg/dl is high (approximately 9%). FH clinical algorithms do not accurately classify patients with FH. Genetic testing should be advocated in young patients with ACS and high LDL-C levels to allow prompt identification of patients with FH and relatives at risk. (C) 2017 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据